Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

read more

Equity Research

Commissioned research by Vator Securities is offered to selected life science companies – "By Invitation Only". Commissioned researches are published continuously.

read more

Vator Securities Unicorn Summit was held on November 27th 2019 at IVA Conferens Center in Stockholm and was attended by over 200 guests.

Click here to watch the presentations

Bio-Works Technologies – Leaving randomness

Bio-Works’s net sales for full year 2019 were SEK 5.6 million, down SEK 1 million from 2018. The decrease is due to the fact that the company’s largest customer in 2018 did not place an order in 2019.

In this update, we have looked beyond Bio-Works’s obvious stochastic character of the order inflow as we believe this is symptomatic for all early commercialization stage companies and not a structural problem for Bio-Works as such.

read more

Swiss Nordic Bio 2020

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet.

Swiss Nordic Bio 2020 will be held on 6 February in Zurich and is a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.

read more

Vator Securities advises SenzaGen on 106 MSEK Directed and Rights Issue

The subscribers in the Directed Share Issue are, amongst other, AP-4 (The Fourth Swedish National Pension Fund), Ålandsbanken Abp, Consensus Asset Management, Kavaljer, Segersta and Thomas Olausson.

read more

AlzeCure Pharma – A win for the amyloid hypothesis is a win for AlzeCure

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case.

The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta.

read more

More News